口袋超声心动图整合移动健康设备评估在现代结构性心脏病门诊中的随机试验
在印度将253例结构性心脏病患者随机分为移动健康设备初诊评估组(n=139)与标准诊疗组(n=114),所有患者均接受全面经胸超声心动图评估疾病严重程度。移动健康组转诊至经皮瓣膜成形术或外科瓣膜置换的时间更短(83±79天 vs 180±101天,p<0.001),1年内住院和/或死亡风险更低(15% vs 28%,校正HR 0.41,95%CI 0.21-0.83,p=0.013)。
要点
- 移动健康设备初诊评估与结构性心脏病患者转诊至确定性治疗的时间缩短相关(83±79天 vs 180±101天,p<0.001)。
- 移动健康组1年内住院和/或死亡风险低于标准诊疗组(15% vs 28%,校正HR 0.41,95%CI 0.21-0.83,p=0.013)。
- 所有患者均接受全面经胸超声心动图评估结构性心脏病严重程度,作为诊断参考标准。
核心结论
- 在资源有限地区,移动健康诊断策略与结构性心脏病患者更短的确定性治疗时间和更好的结局相关。
研究设计与样本
- 随机对照试验,共纳入253例结构性心脏病患者,移动健康组139例、标准诊疗组114例,在印度开展;移动健康门诊配备口袋超声心动图、智能手机连接的心电图血压和血氧测量、活动监测及便携式脑钠肽实验室检测;所有患者均接受全面经胸超声心动图评估结构性心脏病严重程度。
诊断标准与关键数值
- 主要终点为转诊至经皮瓣膜成形术或外科瓣膜置换的时间:移动健康组83±79天 vs 标准诊疗组180±101天,p<0.001。
- 转诊至瓣膜成形术/瓣膜置换的概率:移动健康组34% vs 标准诊疗组32%,校正HR 1.54,95%CI 0.96-2.47,p=0.07。
- 1年内住院和/或死亡概率:移动健康组15% vs 标准诊疗组28%,校正HR 0.41,95%CI 0.21-0.83,p=0.013。
临床应用与阅片要点
- 移动健康设备评估可作为结构性心脏病门诊的临床决策支持工具,本研究中与更短的转诊时间和更低的住院和/或死亡风险相关。
- 所有患者均接受全面经胸超声心动图评估结构性心脏病严重程度,提示口袋超声心动图初筛后仍需全面超声心动图评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to determine whether mobile health (mHealth) device assessments used as clinical decision support tools at the point-of-care can reduce the time to treatment and improve long-term outcomes among patients with rheumatic and structural heart diseases (SHD).
BACKGROUND: Newly developed smartphone-connected mHealth devices represent promising methods to diagnose common diseases in resource-limited areas; however, the impact of technology-based care on long-term outcomes has not been rigorously evaluated.
METHODS: A total of 253 patients with SHD were randomized to an initial diagnostic assessment with wireless devices in mHealth clinics (n = 139) or to standard-care (n = 114) in India. mHealth clinics were equipped with point-of-care devices including pocket-echocardiography, smartphone-connected-electrocardiogram blood pressure and oxygen measurements, activity monitoring, and portable brain natriuretic peptide laboratory testing. All individuals underwent comprehensive transthoracic echocardiography to assess the severity of SHD. The primary endpoint was the time to referral for therapy with percutaneous valvuloplasty or surgical valve replacement. Secondary endpoints included the probability of a cardiovascular hospitalization and/or death over 1 year.
RESULTS: An initial mHealth assessment was associated with a shorter time to referral for valvuloplasty and/or valve replacement (83 ± 79 days vs. 180 ± 101 days; p <0.001) and was associated with an increased probability for valvuloplasty/valve replacement compared to standard-care (34% vs. 32%; adjusted hazard ratio: 1.54; 95% CI: 0.96 to 2.47; p = 0.07). Patients randomized to mHealth were associated with a lower risk of a hospitalization and/or death on follow-up (15% vs. 28%, adjusted hazard ratio: 0.41; 95% CI: 0.21 to 0.83; p = 0.013).
CONCLUSIONS: An initial mHealth diagnostic strategy was associated with a shorter time to definitive therapy among patients with SHD in a resource-limited area and was associated with improved outcomes. (A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics; NCT02881398).
引用
- Bhavnani SP, Sola S, Adams D, et al. A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics. JACC Cardiovasc Imaging. 2017. PMID: 28917688. doi:10.1016/j.jcmg.2017.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。